证券代码：603882 证券简称：金域医学 公告编号：2023-032 广州金域医学检验集团股份有限公司 具体内容详见同日于上海证券交易所网站（www.sse.com.cn）及公司指定披 露媒体《中国证券报》、《上海证券报》、《证券日报》、《证券时报》刊登的《广州 金域医学检验集团股份有限公司关于出售全资子公司部分股权及放弃增资优先 1 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第三届董事会第 十二次会议于 2023 年 8 月 11 日以通讯方式召开。会议通知以电子形式发出，经 全体董事一致同意豁免会议通知期限。会议由董事长梁耀铭先生主持，本次会议 应出席董事 9 名，实际出席董事 9 名。公司监事及高级管理人员列席本次会议。 会议召开符合《中华人民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以记名投票 表决方式通过以下决议： （一）审议通过《广州金域医学检验集团股份有限公司关于出售全资子公 司部分股权及放弃增资优先认购权暨关联交易的议案》 经审议，董事会认为公司出售全资子公司广州金墁利医药科技有 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第三届监事会第 十二次会议于 2023 年 8 月 11 日以通讯方式召开。会议通知以电子形式发出，经 全体监事一致同意豁免会议通知期限，会议由监事会主席陈永坚先生主持，本次 会议应出席监事 3 名，实际出席监事 3 名。本次会议的通知和召开程序符合《中 华人民共和国公司法》、《广州金域医学检验集团股份有限公司章程》的相关规定， 本次会议及其决议合法有效。 二、监事会会议审议情况 证券代码：603882 证券简称：金域医学 公告编号：2023-033 广州金域医学检验集团股份有限公司 第三届监事会第十二次会议决议公告 交易的公告》（公告编号：2023-034）。 特此公告。 广州金域医学检验集团股份有限公司监事会 2023 年 8 月 12 日 2 （一）审议《广州金域医学检验集团股份有限公司关于出售全资子公司部分 股权及放弃增资优先认购权暨关联交易的议案》 表决结果：邹小凤女士及周丽琴女士作为关联监事回 ...

1、会议审议了《广州金域医学检验集团股份有限公司关于出售全资子公司部分 股权及放弃增资优先认购权暨关联交易的议案》,本次出售子公司部分股权 及放弃增资优先认购权的交易符合公司发展战略的需要，遵循了市场公开、 公平的原则,审议程序符合《公司法》、《上海证券交易所股票上市规则》 和《公司章程》的相关规定,关联董事均回避表决,不存在损害公司和全体 股东、特别是非关联股东和中小投资股东利益的情形。本次股权交易作价公 司结合了投资成本和必要收益,参考评估机构对广州金漫利医药科技有限公 司出具的《评估报告》,经各方友好协商确定,交易价格公允合理,不存在 损害公司利益的情况。我们一致同意公司出售全资子公司部分股权及放弃增 资优先认购权暨关联交易事项。 (以下无正文) 广州金域医学检验集团股份有限公司 独立董事对公司相关事项发表的独立意见 根据《上市公司独立董事规则》、《上海证券交易所股票上市规则》和《公 司章程》等的有关规定,我们作为广州金域医学检验集团股份有限公司（以下简 称"公司"）独立董事，审阅了公司第三届董事会第十二次会议的有关材料后, 并基于独立判断立场,发表如下独立意见: (本页无正文,为《独立董事对公司相关事 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 证券代码：603882 证券简称：金域医学 公告编号：2023-035 广州金域医学检验集团股份有限公司 关于召开 2023 年第一次临时股东大会的通知 2023 年第一次临时股东大会 召开地点：金域医学总部大楼 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 8 月 28 日 至 2023 年 8 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 1 股东大会召开日期：2023年8月28日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2023 年 8 月 28 日 14 点 00 分 东大会召开当日的交 ...

广州金域医学检验集团股份有限公司 独立董事事前认可意见 经核查,我们认为本次交易符合公司发展战略的需要,交易双方以平等互利 为基础,遵循市场化原则,交易价格合理、公允,符合有关法律、法规的要求和 《公司章程》的规定,不存在损害公司和全体股东,特别是中小股东的利益的情 形,同意提交公司第三届董事会第十二次董事会审议。关联董事应回避表决。 8月9日 2023年 (以下无正文) （本页无正文,为广州金域医学检验集团股份有限公司独立董事事前认可意见之 签字页 ) 独立董事签字: 8 月 2023年 日 P （本页无正文,为广州金域医学检验集团股份有限公司独立董事事前认可意见之 签字页 ) 根据《上市公司独立董事规则》、《上海证券交易所股票上市规则》等法律法 规及《广州金域医学检验集团股份有限公司章程》(以下简称"《公司章程》")、 《关联交易管理制度》等规章制度的有关规定,就广州金域医学检验集团股份有 限公司（以下简称"公司"）关于出售全资子公司部分股权及放弃增资优先认购 权暨关联交易的事项进行了认真的事前核查。我们基于独立、客观判断的原则, 对该事项发表如下意见: 独立董事签字: 日 2023年8月9 (本页无正文 ...

证券代码：603882 证券简称：金域医学 公告编号：2023-034 广州金域医学检验集团股份有限公司 关于出售全资子公司部分股权及放弃增资优先认购 权暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 交易简要内容：公司拟按照估值 30,780 万元向鑫鸿域、鑫泓瑞、鑫墁利及 公司高级管理人员谢江涛分别出售全资子公司金墁利 20.4057%、14.4717%、 31.0675%及 6.0551%股权，交易金额分别为人民币 6,280.87 万元、4,454.39 万元、9,562.58 万元及 1,863.76 万元，合计转让 72% 的股权，交易金额总计 22,161.60 万元人民币。同时，因金墁利业务发展需要，转让完成后，鑫鸿 域、鑫泓瑞、鑫墁利、谢江涛将分别向金墁利按照 30,780 万元估值增资 459.13 万元、325.61 万元、699.02 万元、136.24 万元，合计增资 1,620 万元， 公司放弃行使优先认购权。增资完成后金域医学、鑫鸿域、鑫泓瑞、鑫墁 利、谢江涛 ...

证券代码：603882 证券简称：金域医学 公告编号：2023-018 广州金域医学检验集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 5 月 11 日(星期四)至 5 月 17 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司董事会办公室 邮箱 sid@kingmed.com.cn 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 广州金域医学检验集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发布公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者更 全面深入地了解公司 2022 年度及 2023 年第一季度的经营成果、财务状况，公司 计划于 2023 年 5 月 18 日上午 10:00-11:30 举行 2022 年度暨 2023 年第一季度业 绩说明会（以下简称"业绩说明会"），就投资者关心的问题进行交 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,117,566,265.14, a decrease of 50.19% compared to the same period last year[4] - Net profit attributable to shareholders was ¥149,613,208.46, down 82.40% year-on-year, while the net profit excluding non-recurring gains and losses decreased by 83.20%[4] - The diluted earnings per share were ¥0.32, reflecting an 82.42% decrease compared to the previous year[5] - Net profit for Q1 2023 was ¥140,616,978.25, a decline of 84.6% compared to ¥909,423,394.29 in Q1 2022[17] - Comprehensive income for Q1 2023 totaled ¥125,746,509.44, a decrease of 86.1% from ¥908,396,159.29 in Q1 2022[18] Cash Flow and Management - The net cash flow from operating activities was ¥219,822,454.05, an increase of 143.47% year-on-year, indicating improved cash management[4] - In Q1 2023, the net cash flow from operating activities was RMB 219,822,454.05, a significant increase from RMB 90,285,681.91 in Q1 2022, representing a growth of approximately 143.5%[20] - Total cash inflow from operating activities was RMB 2,471,627,822.23, while cash outflow was RMB 2,251,805,368.18, resulting in a net cash inflow of RMB 219,822,454.05[20] - Cash and cash equivalents at the end of Q1 2023 amounted to RMB 2,926,679,233.87, up from RMB 2,453,855,010.63 at the end of Q1 2022, indicating an increase of approximately 19.2%[20] - The company reported a decrease in cash paid for goods and services, which was RMB 1,027,974,829.24 in Q1 2023 compared to RMB 1,149,933,502.11 in Q1 2022, reflecting a reduction of about 10.6%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥13,409,369,919.34, a decrease of 3.47% from the end of the previous year[5] - As of March 31, 2023, the total current assets amounted to RMB 10,124,855,451.83, a decrease of 5.03% from RMB 10,659,634,227.24 on December 31, 2022[13] - Total non-current assets increased slightly to RMB 3,284,514,467.51 from RMB 3,231,073,610.50, an increase of 1.65%[14] - The company's total liabilities decreased to ¥4,388,202,903.12 in Q1 2023 from ¥5,015,880,313.01 in Q1 2022[15] - Accounts payable decreased to RMB 2,749,070,254.25 from RMB 2,988,243,259.98, a decrease of 8.01%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,752[10] - The largest shareholder, Liang Yaoming, holds 15.88% of the shares, with a total of 74,191,907 shares[10] - The company reported a total of 71,068,209 shares held by the largest shareholder, Liang Yaoming, representing 7.12% of the total shares[12] Operational Strategy - The company aims to enhance operational efficiency and improve quality and efficiency in 2023, focusing on refined management strategies[5] Research and Development - Research and development expenses for Q1 2023 were ¥131,642,934.47, a slight decrease from ¥142,105,900.23 in Q1 2022[16] - The company has not disclosed any new product or technology developments during the reporting period[12] Mergers and Acquisitions - There are no significant mergers or acquisitions reported in the current quarter[12] Accounting Standards - The company implemented new accounting standards starting January 1, 2023, which may affect the financial statements and reported figures[21]

Financial Performance - In 2022, the company achieved a revenue of 15.476 billion yuan, representing a year-on-year growth of 29.58%[2] - The net profit attributable to shareholders was 2.753 billion yuan, with a year-on-year increase of 24.02%[2] - The company reported a total revenue of 1.5 billion RMB for the year 2022, representing a year-on-year growth of 15%[12] - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[110] - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[115] - The company provided a performance guidance for 2023, expecting a revenue growth of 10% to 15%[12] - The company has set a revenue guidance for 2023, projecting an increase of 25% to reach approximately 1.875 billion RMB[15] - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% to 1.875 billion RMB[110] - The company achieved operating revenue of ¥15,476,074,538.17, representing a year-on-year growth of 29.58%[64] - The net profit attributable to shareholders was ¥2,752,785,213.09, reflecting a year-on-year increase of 24.02%[64] Strategic Initiatives - The company plans to enhance its digital transformation and innovation efforts, focusing on clinical challenges and integrating technology[4] - The strategic focus for 2023 includes high-quality development and digital transformation as core directions[4] - The company aims to improve operational efficiency and resource mobilization through a "project-based" operational reform[4] - The company is committed to becoming a leading global medical testing group, contributing to the "Healthy China" initiative[4] - The company is exploring potential mergers and acquisitions to strengthen its competitive position in the market[19] - The company is actively pursuing strategic initiatives to enhance investor relations and corporate governance practices[103] - The company plans to continue its market expansion and product development strategies in the upcoming year[120] Research and Development - Investment in research and development increased by 30%, focusing on innovative diagnostic technologies[12] - The company is focusing on the development of new technologies and products, including precision medicine and advanced diagnostic methods[19] - The company has established three major R&D centers in Guangzhou, Shanghai, and Beijing, enhancing its R&D planning and support capabilities[39] - The company has integrated 7 directions and 27 popular research areas, successfully advancing major R&D projects in aging biomarkers, whole genome sequencing (WGS), and rare pathogen detection[47] - The company is investing in research and development, allocating 10% of its revenue towards innovative testing technologies and methodologies[15] - Ongoing research and development efforts are focused on innovative testing technologies, with an investment of 200 million RMB allocated for the upcoming year[110] Market Expansion - The company is expanding its market presence with plans to open 10 new testing centers across China in 2023[12] - The company is expanding its market presence by opening 10 new laboratories across key regions in China, aiming to improve accessibility to its services[15] - The company is exploring international expansion opportunities, particularly in Southeast Asia[12] - The company aims to enhance its core capabilities in clinical services and expand its market presence in top-tier hospitals, focusing on precision collaboration[89] - The company is expanding its market presence, targeting an additional 10 provinces in China by the end of the next fiscal year[116] Operational Efficiency - The company aims to enhance operational efficiency, targeting a reduction in operational costs by 10% in 2023[12] - The company's operating revenue for the current period is ¥15,476,074,538.17, representing a 29.58% increase compared to ¥11,943,223,630.06 in the same period last year[65] - The gross profit margin improved to 45%, up from 42% in the previous year[12] - The laboratory's operational efficiency has improved by over 20% through the implementation of a dry-wet separation production model[42] - The company is focusing on improving operational efficiency and cost control across various functions, including marketing, logistics, and risk management[93] Talent Development - The company emphasizes the cultivation of high-quality talent to support its growth and development[4] - The company has a talent pool of over 4,300 professionals, including 10 experts receiving State Council subsidies and more than 200 renowned experts from home and abroad[63] - The company plans to strengthen its talent development initiatives by increasing job rotation and project team assignments to cultivate versatile talents[93] Social Responsibility - The company invested a total of 39.06 million yuan in social responsibility projects, with 31.71 million yuan allocated for funding and 7.36 million yuan for material donations[166] - The company has established or collaborated to build 100 medical laboratories in 87 poverty alleviation counties, serving over 9,000 medical institutions and benefiting more than 100 million people[170] - The company conducted 12 health public welfare activities, including initiatives for hearing health and tuberculosis screening[168] - The company received multiple awards for its social responsibility efforts, including the "2022 Sustainable Development Model Enterprise" award[168] Compliance and Governance - The company has established a remuneration committee to determine the compensation of directors and senior management based on overall performance indicators[118] - The company has not faced any penalties from securities regulatory authorities in the past three years[118] - The company has ensured that minority shareholders have sufficient opportunities to express their opinions and protect their legal rights[137] - The company has committed to ensuring that major shareholders do not interfere with its management or infringe on its interests[180] Environmental Initiatives - The company has established a comprehensive ISO 14001 environmental management system to ensure compliance with environmental regulations and reduce carbon emissions[158] - The company has implemented a specific emergency plan for sudden environmental incidents, identifying potential environmental risks[154] - The company has developed an annual self-monitoring plan for environmental monitoring, engaging qualified third-party testing agencies[155] - The company has reduced comprehensive energy consumption per 10,000 yuan of total output value year by year, indicating improved energy efficiency[164] Risks and Challenges - The company has faced policy risks due to ongoing healthcare reforms and changes in medical payment methods, which may impact industry development[95] - The company is encountering market risks from increased scrutiny and competition in the third-party medical testing industry, affecting service quality and operational management[95] - The company recognizes technology risks from the emergence of new technologies such as POCT and AI, which require continuous adaptation to maintain competitive advantage[97]

Financial Performance - In 2021, the company achieved operating revenue of CNY 11,943,223,630.06, representing a year-on-year growth of 44.88%[2] - The net profit attributable to shareholders was CNY 2,219,640,445.22, with a year-on-year increase of 47.03%[2] - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[12] - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2021, representing a year-over-year growth of 25%[18] - The company achieved a net cash flow from operating activities of CNY 2,087,970,590.35, a 37.09% increase from CNY 1,523,107,566.84 in 2020[26] - The company's total assets at the end of 2021 were CNY 10,750,891,917.56, a 61.93% increase from CNY 6,639,312,967.40 at the end of 2020[28] - The basic earnings per share for 2021 were CNY 4.80, reflecting a 45.90% increase from CNY 3.29 in 2020[29] - The overall gross profit margin for the reporting period was 47.29%, an increase of 0.60 percentage points compared to the previous year[61] - The gross profit margin improved to 45%, up from 40% in the previous year, indicating better cost management and operational efficiency[12] Research and Development - The company established over 150 partnerships for research and innovation, expanding its technological ecosystem[3] - Investment in R&D increased by 30%, focusing on innovative diagnostic technologies and expanding the product portfolio[12] - Research and development expenses increased by 30.40% to CNY 517,928,365.75, reflecting a commitment to innovation[60] - The company is focusing on high-quality development and innovation-driven strategies to enhance clinical service capabilities and strengthen partnerships with high-level medical institutions[47] - The company aims to enhance its R&D capabilities and align with international standards through strategic collaborations[4] Market Expansion and Strategy - The company plans to expand its market presence by opening 15 new testing centers across major cities in China in the upcoming year[12] - The company is expanding its market presence by entering three new provinces in China, aiming to increase its service coverage by 15%[19] - The company is positioned to benefit from the ongoing healthcare reforms and the growing demand for third-party medical testing services[40] - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% driven by new product launches and market expansion[12] - The company is actively pursuing partnerships in research and development, with 22 new collaborations established during the reporting period[38] Digital Transformation - The company is focused on digital transformation to improve service quality and cost-effectiveness in medical testing[5] - The company aims to enhance its digital services, with a target of increasing online test bookings by 50% in the next year[12] - The company is focusing on digital transformation by leveraging big data and implementing "smart laboratory" projects to enhance customer service and operational efficiency[86] - The company is exploring strategic partnerships with internet medical enterprises to enhance its service offerings and digital transformation[77] Sustainability and Corporate Responsibility - The company received an AA rating from MSCI ESG, highlighting its commitment to sustainable practices[3] - A commitment to sustainability was highlighted, with plans to reduce operational carbon emissions by 20% by 2025[12] - The company has implemented a green office strategy, significantly reducing electricity consumption through energy-efficient air conditioning and lighting systems[156] - The company has established a comprehensive medical waste management program to ensure compliance with national standards for medical waste disposal[154] - The company invested 1,656.33 million yuan in industrial assistance in poverty alleviation areas, establishing 100 laboratories to enhance local medical service capabilities[159] Operational Efficiency - The overall operational efficiency has improved, with a reported reduction in costs by 5% due to optimized processes and technology integration[19] - The company aims to improve laboratory management efficiency by establishing a maturity assessment model and optimizing operational costs through information technology[86] - The company aims to reduce operational costs by 15% through efficiency improvements and technology upgrades[101] Governance and Management - The company is committed to maintaining transparency in its financial reporting and governance practices[111] - The company has established a high-quality talent management mechanism to support its strategic development and optimize performance evaluation systems[87] - The company has implemented a long-term incentive plan for directors and senior management, linking performance measures to the execution of return compensation measures[175] - The company has maintained a stable management team with no significant changes in senior management positions reported[97] Shareholder Engagement and Returns - A cash dividend of CNY 1.28 per share (before tax) was proposed based on a total share capital of 465,586,275 shares[8] - The company commits to distributing cash dividends of at least 10% of the distributable profits each year for the next three years, with a cumulative distribution of no less than 30% of the average annual distributable profits over that period[163] - The company plans to review its shareholder return plan at least every three years, taking into account the opinions of shareholders and independent directors[163] Challenges and Industry Outlook - The company faces challenges due to unclear regulations regarding third-party medical testing institutions and potential quality discrepancies in the industry[78] - The third-party medical testing industry in China is estimated to have a market size of approximately ¥39 billion, with significant growth potential compared to developed countries[76] - The COVID-19 pandemic has accelerated the growth of third-party medical testing laboratories, enhancing their operational standards and capacity, particularly in large-scale nucleic acid testing[46]